Since the publication of the REPRIEVE trial last summer in The New England Journal of Medicine,1 there has been renewed interest and enthusiasm for cardiovascular disease (CVD) prevention for people living with HIV (PLWH). Regardless of how you feel about the benefits of statins, we can all agree that helping our patients live long and healthy lives requires us to look beyond the HIV care cascade to consider the prevention of non-AIDS comorbidities, including CVD.2
Taking a